Tag Archives: drug development

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research

alzheimers

Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Real Reason Why Salk Refused to Patent the Polio Vaccine

Vaccine

A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent.  Could you patent the sun?”  Many use this statement as the moral impetus for refusing patents on medically important innovations (see Michael Moore’s Capitalism: A Love Story).  Unfortunately, Jonas Salk created a myth that day by leaving out several crucial details. As pointed out by Robert Cook-Deegan at Read More >

Patently BIOtech  |  16 Comments  |  Email This Post
Tags: , , , , , , ,

IBM’s Watson: From Jeopardy! to Drug Research

IBM's Watson Computer System Plays Jeopardy! in a Practice Round

Bits of technology from I.B.M.’s Watson are beginning to be used in actual products available to corporate clients. The cloud-based Strategic Intellectual Property Insight Platform “uses data mining, natural-language processing and analytics to pore through millions of patent filings and biomedical journals to look for chemical compounds used in drug discovery.” As a byproduct of this project, I.B.M. is contributing their research to the searchable NIH chemical database, which will ease access to information previously Read More >

Health  |  1 Comment  |  Email This Post
Tags: , ,

Where’s the Deal?

2011-drug-deals-thumb

With only two weeks to go in 2011 it is looking like a five year low for deals. The chart below shows therapeutic deals dropping every year since 2007. We use the Windhover/Elsevier Strategic Transaction Database as our starting point for deal analytics. We analyze each deal to determine if the deal is for a drug asset, removing generic/OTC deals, manufacturing/service deals, device/diagnostics/tools deals, and tech transfer deals. What remains are deals for biotech company Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Diabetes and Biotechnology: A Shared History…A Great Future

diabetes-thumb

By David Welch, President/Senior Producer at M2 MultiMedia One of my closest childhood friends suffered from Type I Diabetes. Like millions of other children and adults his daily life was frequently interrupted with finger pokes, sugar level tests, and insulin shots. Having grown up with a friend afflicted with Diabetes and knowing dozens of others, throughout my life, with the same disease, it was very rewarding to produce a film on the topic. Although Bobby and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,